Christina Mcgraw, MA, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1700 Steiger Lake Lane, #208, Victoria, MN 55386 Phone: 612-750-6725 |
Kristin Beety Cole, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 4999 Obsidian Way, Victoria, MN 55386 Phone: 952-239-2322 |
Amy Elizabeth Spivey Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 1772 Stieger Lake Ln, Victoria, MN 55386 Phone: 952-443-4600 Fax: 952-443-4604 |
Jennifer Susan Johnson, MA Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1772 Steiger Lake Ln, #220, Victoria, MN 55386 Phone: 952-443-4600 |
Eric Raisler, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1772 Steiger Lake Ln, Victoria, MN 55386 Phone: 952-443-4600 |
Katie Ernst, MA, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 1772 Stieger Lake Ln Ste 220, Victoria, MN 55386 Phone: 952-443-4600 Fax: 952-443-4604 |
Dana Jo Oxendale, M.A. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1772 Stieger Lake Ln Ste 200, Victoria, MN 55386 Phone: 651-442-7836 |
News Archive
A research team from National University of Singapore has developed a soft, flexible and stretchable microfibre sensor for real-time healthcare monitoring and diagnosis.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.
BioMedical Enterprises has announced that the U.S. Patent Office awarded BME with the patent for "System and Method for Force, Displacement and Rate Control of Shape Memory Material Implants."
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
Many people don't realise that how they take their vitamin and mineral supplements is just as important as what they take.
› Verified 3 days ago